Actavis may buy Warner Chilcott

Share this article:

Actavis' Friday announcement that it is in talks to take over Warner Chilcott is a signal that 2013 is going to be one of transformation for the umbrella company that was known as Watson Pharmaceuticals until January. Watson bought Switzerland-based Actavis in October 2012, a move that created the world's third-largest generics pharmaceutical drug company. Post-merger, Actavis had $1.5 billion in sales and threw $98.8 million toward R&D for the period ended March 31, 2013.  The company said at quarter's close that it expected net revenues to reach around $8.1 billion for the year.

The financial trend is contrary to that of Warner Chilcott, which saw sales slide 13% during the quarter, to $578 million. Sales of its oral contraceptives business rose 6% to $9 million for the quarter, and the FDA approved two new oral contraceptives between April and May. Warner expects to launch the approved ferrous fumarate tablets, known as Minastrin 24 FE in early August, but said in a statement Friday that it is holding off on launching the other oral contraceptive for the time being.

A deal would fatten Actavis' antibiotics, dermatology, women's health and contraceptive portfolio, in addition to adding its line of gastroenterology and urology products.

Both companies said in their respective statements that they would not provide any more detail about the discussions, other than that they are happening.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?